Neurotrophic factor therapy for Parkinson’s disease: Past, present and future

Neural Regeneration Research

Volumn 11, Issue 2, 2016, Pages 205-207

  Sullivan, Aideen M ^a   O’Keeffe, Gerard W ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BONE MORPHOGENETIC PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; NEUROTROPHIC FACTOR; NEURTURIN; PROTEIN RET; RECOMBINANT PROTEIN;

ARTICLE; CELL MATURATION; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; NERVE REGENERATION; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION;

EID: 84962614539     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.177710     Document Type: Article

References (18)

1. Back S, Peranen J, Galli E, Pulkkila P, Lonka-Nevalaita L, Tamminen T, Voutilainen MH, Raasmaja A, Saarma M, Mannisto PT, Tuominen RK (2013) Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson’s disease. Brain Behav 3:75-88
2. Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, Turner DA, Stacy M, Lang AE, Lozano AM, Olanow CW (2013) Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80:1698-1701
3. Barua NU, Bienemann AS, Woolley M, Wyatt MJ, Johnson D, Lewis O, Irving C, Pritchard G, Gill S (2015) Convection-enhanced delivery of MANF - Volume of distribution analysis in porcine putamen and substantia nigra. J Neurol Sci 357:264-269
4. Cordero-Llana O, Houghton BC, Rinaldi F, Taylor H, Yanez-Munoz RJ, Uney JB, Wong LF, Caldwell MA (2015) Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson’s disease. Mol Ther 23:244-254
5. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A (2012) alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 4:163ra156
6. Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Bjorklund A (2011) GDNF fails to exert neuroprotection in a rat alpha- synuclein model of Parkinson’s disease. Brain 134:2302-2311
7. Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595
8. Hegarty SV, O’Keeffe GW, Sullivan AM (2014a) Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson’s disease. Neural Regen Res 9:1708-1711
9. Hegarty SV, Collins LM, Gavin AM, Roche SL, Wyatt SL, Sullivan AM, O’Keeffe GW (2014b) Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons. Neuromolecular Med 16:473-489
10. Kelly MJ, O’Keeffe GW, Sullivan AM (2015) Viral vector delivery of neurotrophic factors for Parkinson’s disease therapy. Exp Rev Mol Med 17: e8,1-14
11. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466
12. Marks WJ, Jr., Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol 7:400-408
13. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, et al. (2010) Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164-1172
14. Olanow WC, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, et al. (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol 78:248-257
15. Richardson RM, Kells AP, Rosenbluth KH, Salegio, EA, Fiandaca, MS, Larson PS, Starr PA, Martin AJ, Lonser, RR, Federoff, HJ, Forsayeth, JR, Bankiewicz KS (2011) Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson’s disease. Mol Ther19:1048-1057
16. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102:216-222
17. Smith RC, O’Bryan LM, Mitchell PJ, Leung D, Ghanem M, Wilson JM, Hanson JC, Sossick S, Cooper J, Huang L, Merchant KM, Lu J, O’Neill MJ (2015) Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF. Exp Neurol 267:165-176
18. Sullivan AM, Toulouse A (2011) Neurotrophic factors for the treatment of Parkinson’s disease. Cytokine Growth Factor Rev 22:157-165.